European journal of gastroenterology & hepatology · 2008
Report on de-novo mutation in the MSH2 gene as a rare event in hereditary nonpolyposis colorectal cancer.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morak Monika, Laner Andreas, Scholz Michael, Madorf Trisari, Holinski-Feder Elke
Аннотация
OBJECTIVE: Hereditary nonpolyposis colorectal cancer (HNPCC) is an autosomal dominant predisposition for early-onset colorectal cancer and associated tumour types caused by mutations in DNA mismatch repair genes, mainly MLH1 and MSH2. The Amsterdam criteria, stressing familial tumour events, as well as the less stringent Bethesda criteria, help to raise suspicion of HNPCC.
RESULT: Mutation screening in a colon cancer patient of young age but negative family history revealed the MSH2 splice site mutation c.2006-2A>G. This mutation was present in all three germ cell layers in the patient, but absent in her biological parents, reporting the second case of de-novo germline mutation in MSH2.
CONCLUSION: Our findings suggest that at least in approximately 1% of mutation-positive cases, a de-novo event might be involved. The identification of a newly evolved rare mutation calls for alertness and encourages the application of the Bethesda guidelines and certain clinical and histopathological features to define candidates for HNPCC gene mutation screening despite a negative family history.
RESULT: Mutation screening in a colon cancer patient of young age but negative family history revealed the MSH2 splice site mutation c.2006-2A>G. This mutation was present in all three germ cell layers in the patient, but absent in her biological parents, reporting the second case of de-novo germline mutation in MSH2.
CONCLUSION: Our findings suggest that at least in approximately 1% of mutation-positive cases, a de-novo event might be involved. The identification of a newly evolved rare mutation calls for alertness and encourages the application of the Bethesda guidelines and certain clinical and histopathological features to define candidates for HNPCC gene mutation screening despite a negative family history.